Lyndal Anderson

Lyndal Anderson

Auto-generated profile, based on publicly available information

Lyndal Anderson

Royal Prince Alfred Hospital Camperdown NSW Australia

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Pathology
Verified
Journal Article
Closed access
EPElizabeth C. Paver
Elizabeth C. Paver
WCWendy A. Cooper
Wendy A. Cooper
ACAndrew J. Colebatch
Andrew J. Colebatch
PFPeter M. Ferguson
Peter M. Ferguson
SHSean K. Hill
Sean K. Hill
RGRuta Gupta
Ruta Gupta

1 January 2019 in Sage Open Medicine
Verified
Journal Article
Open access
PDF file
NNNjume Peter Nijkang
Njume Peter Nijkang
LALyndal Anderson
Lyndal Anderson
RMRobert Markham
Robert Markham
FMFrank Manconi
Frank Manconi
Endometrial polyps are overgrowths of endometrial glands that typically protrude into the uterine cavity. Endometrial polyps are benign in nature and affect both reproductive age and postmenopausal women. Although endometrial polyps are relatively common and may be accompanied by abnormally heavy bleeding at menstruation. In asymptomatic women, endometrial polyps may regress spontaneously, in symptomatic women endometrial polyps can be treated safely and efficiently with hysteroscopic excision.

1 May 2016 in American Journal of Surgical Pathology
Verified
Journal Article
Open access
WHWesley J. Harrison
Wesley J. Harrison
JAJuliana Andrici
Juliana Andrici
FMFiona Maclean
Fiona Maclean
RMRaha Madadi-Ghahan
Raha Madadi-Ghahan
MFMahtab Farzin
Mahtab Farzin
AGAnthony J. Gill
Anthony J. Gill
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome secondary to germline fumarate hydratase (FH) mutation presents with cutaneous and uterine leiomyomas, and a distinctive aggressive renal carcinoma. Identification of HLRCC patients presenting first with uterine leiomyomas may allow early intervention for renal carcinoma. We reviewed the morphology and immunohistochemical (IHC) findings in patients with uterine leiomyomas and confirmed or presumed HLRCC. IHC was also performed on a tissue microarray of unselected uterine leiomyomas and leiomyosarcomas. FH-deficient leiomyomas underwent Sanger and massively parallel sequencing on formalin-fixed paraffin-embedded tissue. All 5 patients with HLRCC had at least 1 FH-deficient leiomyoma: defined as completely negative FH staining with positive internal controls. One percent (12/1152) of unselected uterine leiomyomas but 0 of 88 leiomyosarcomas were FH deficient. FH-deficient leiomyoma patients were younger (42.7 vs. 48.8 y, P=0.024) and commonly demonstrated a distinctive hemangiopericytomatous vasculature. Other features reported to be associated with FH-deficient leiomyomas (hypercellularity, nuclear atypia, inclusion-like nucleoli, stromal edema) were inconstantly present. Somatic FH mutations were identified in 6 of 10 informative unselected FH-deficient leiomyomas. None of these mutations were found in the germline. We conclude that, while the great majority of patients with HLRCC will have FH-deficient leiomyomas, 1% of all uterine leiomyomas are FH deficient usually due to somatic inactivation. Although IHC screening for FH may have a role in confirming patients at high risk for hereditary disease before genetic testing, prospective identification of FH-deficient leiomyomas is of limited clinical benefit in screening unselected patients because of the relatively high incidence of somatic mutations.

31 July 2017 in Oncogenesis
Verified
Journal Article
Open access
PDF file
AMA D Marshall
A D Marshall
MGM van Geldermalsen
M van Geldermalsen
NON J Otte
N J Otte
TLT Lum
T Lum
MVM Vellozzi
M Vellozzi
JHJ Holst
J Holst
Glutamine commonly becomes a conditionally essential amino acid in cancer. Glutamine is supplied to the cell by transporters such as ASCT2 (SLC1A5), which is frequently upregulated in multiple cancers. Here we investigated the expression of ASCT2 in endometrial carcinoma, and evaluated the contribution of ASCT2 to glutamine uptake and endometrial cancer cell growth. Analysis of human gene expression data showed that ASCT2 was significantly upregulated in both endometrioid and serous subtypes of endometrial carcinoma, compared to normal, age-matched endometrium. Furthermore, immunohistochemical staining of primary human endometrioid adenocarcinomas showed that tumours stain positive for ASCT2 in either a uniform or mosaic expression pattern, while normal adjacent glands appeared predominantly negative for ASCT2 staining. Chemical inhibition of glutamine transport by benzylserine or GPNA led to a significant decrease in endometrial cancer cell growth and spheroid cross-sectional area. ASCT2 knockdown recapitulated the decrease of cell growth and spheroid cross-sectional area in HEC1A cells, suggesting a reliance on ASCT2-mediated glutamine uptake. ASCT2 knockdown in Ishikawa cells led to lower glutamine uptake and cell growth, but did not affect spheroid area. Ishikawa cells express higher levels of the glutamine transporter SNAT1 compared to HEC1A cells, suggesting these cells may rely on both ASCT2 and SNAT1 for glutamine uptake. Since SNAT1 is also significantly upregulated in the endometrioid and serous subtypes, these data indicate that ASCT2 and SNAT1 could be used as markers of malignancy, and/or potential therapeutic targets in patients with endometrial carcinoma.

14 July 2017 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
JBJulia M.L. Brotherton
Julia M.L. Brotherton
STSepehr N. Tabrizi
Sepehr N. Tabrizi
SPSamuel Phillips
Samuel Phillips
JPJan Pyman
Jan Pyman
ACAlyssa M. Cornall
Alyssa M. Cornall
SGSuzanne M. Garland
Suzanne M. Garland

20 March 2017 in Oncogene
Verified
Journal Article
Open access
AMA D Marshall
A D Marshall
Charles BaileyCharles Bailey
Charles Bailey
KCK Champ
K Champ
MVM Vellozzi
M Vellozzi
POP O'YOung
P O'YOung
JRJohn E.J. Rasko
John E.J. Rasko
CTCF is a haploinsufficient tumour suppressor gene with diverse normal functions in genome structure and gene regulation. However the mechanism by which CTCF haploinsufficiency contributes to cancer development is not well understood. CTCF is frequently mutated in endometrial cancer. Here we show that most CTCF mutations effectively result in CTCF haploinsufficiency through nonsense-mediated decay of mutant transcripts, or loss-of-function missense mutation. Conversely, we identified a recurrent CTCF mutation K365T, which alters a DNA binding residue, and acts as a gain-of-function mutation enhancing cell survival. CTCF genetic deletion occurs predominantly in poor prognosis serous subtype tumours, and this genetic deletion is associated with poor overall survival. In addition, we have shown that CTCF haploinsufficiency also occurs in poor prognosis endometrial clear cell carcinomas and has some association with endometrial cancer relapse and metastasis. Using shRNA targeting CTCF to recapitulate CTCF haploinsufficiency, we have identified a novel role for CTCF in the regulation of cellular polarity of endometrial glandular epithelium. Overall, we have identified two novel pro-tumorigenic roles (promoting cell survival and altering cell polarity) for genetic alterations of CTCF in endometrial cancer.